Literature DB >> 7742725

Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.

J P Struewing1, C Lerman, R G Kase, T R Giambarresi, M A Tucker.   

Abstract

In anticipation of the identification of the BRCA1 gene, we studied the interest in and anticipated reaction to DNA testing for mutations in this gene in members of high-risk families. We surveyed 91 female and 49 male subjects using a structured interview by study nurses. All subjects were members of inherited breast-ovarian cancer families participating in a genetic linkage study at the National Cancer Institute. The main outcomes of the study were interest in genetic testing and anticipated impact of test results. Seventy nine % of subjects indicated that they would "definitely" want to be tested, and 16% would "probably" want to be tested for mutations in the BRCA1 gene. Subjects with a high self-perceived risk of having an altered BRCA1 gene were more likely to definitely want testing (P = 0.02), while estimated true genetic risk did not predict interest in the test. Females were significantly more likely to definitely want testing (P = 0.005) and had a significantly greater mean anticipated negative-impact score (2.3) compared to males (1.0) (P < 0.001). We found a high level of interest in genetic testing for BRCA1 among members of inherited breast-ovarian cancer families participating in a genetic linkage study. While utilization may fall below levels of interest reported in this and other preliminary surveys, given the potential for early detection and treatment of breast and ovarian cancer, interest in BRCA1 testing may translate into high rates of uptake. These results indicate that it will be critical to incorporate follow-up counseling and support into BRCA1 testing programs.

Entities:  

Mesh:

Year:  1995        PMID: 7742725

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  43 in total

1.  Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway.

Authors:  Trine Levin Bodd; Jon Reichelt; Ketil Heimdal; Pal Moller
Journal:  J Genet Couns       Date:  2003-10       Impact factor: 2.537

2.  Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: breast cancer survivors compared with healthy controls.

Authors:  Michael A Andrykowski; Jessica L Burris; Erin Walsh; Brent J Small; Paul B Jacobsen
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

3.  Uptake of genetic testing for cancer predisposition.

Authors:  D G Evans; E R Maher; R Macleod; D R Davies; D Craufurd
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

4.  Predictive Genetic Testing and Alternatives to Face to Face Results Disclosure: A Retrospective Review of Patients Preference for Alternative Modes of BRCA 1 and 2 Results Disclosure in the Republic of Ireland.

Authors:  Rosie O'Shea; Marie Meany; Cliona Carroll; Nuala Cody; David Healy; Andrew Green; Sally Ann Lynch
Journal:  J Genet Couns       Date:  2015-09-26       Impact factor: 2.537

5.  Evaluating the impact of genetic counseling and testing with signal detection methods.

Authors:  Christina G S Palmer; Donald W Hadley
Journal:  J Genet Couns       Date:  2005-02       Impact factor: 2.537

6.  Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines.

Authors:  Julia Hall; Susan Gray; Roger A'Hern; Susan Shanley; Maggie Watson; Kathryn Kash; Robert Croyle; Rosalind Eeles
Journal:  Fam Cancer       Date:  2008-08-05       Impact factor: 2.375

Review 7.  Cancers related to genetic mutations: important psychosocial issues for Canadian family physicians.

Authors:  Tara E Power; John Robinson
Journal:  Can Fam Physician       Date:  2006-11       Impact factor: 3.275

8.  Utilizing Focus Groups with Potential Participants and Their Parents: An Approach to Inform Study Design in a Large Clinical Trial.

Authors:  Sandeep Kadimpati; Jennifer B McCormick; Yichen Chiu; Ashley B Parker; Aliya Z Iftikhar; Randall P Flick; David O Warner
Journal:  AJOB Empir Bioeth       Date:  2014-01-01

9.  Patient satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial.

Authors:  Jennifer R Klemp; Anne O'Dea; Carolyn Chamberlain; Carol J Fabian
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 10.  [Value of breast MRI as supplement to mammography and sonography for high risk breast cancer patients].

Authors:  T Schlossbauer; K Hellerhoff; M Reiser
Journal:  Radiologe       Date:  2008-04       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.